Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms (Vol 12, 37, 2022)

被引：0
|
作者：
Hu, Mengshi
Yang, Tao
Yang, Linyu
Niu, Lu
Zhu, Jinbing
Zhao, Ailin
Shi, Mingsong
Yuan, Xue
Tang, Minghai
Yang, Jianhong
Pei, Heying
Yang, Zhuang
Chen, Qiang
Ye, Haoyu
Niu, Ting
Chen, Lijuan
机构：
[1] West China Hospital of Sichuan University,State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics
[2] West China Hospital of Sichuan University,Department of Hematology and Research Laboratory of Hematology
[3] Chengdu Zenitar Biomedical Technology Co.,undefined
[4] Ltd,undefined
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01058-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
    Zhang, Shu-Peng
    Li, Hui
    Lai, Ren-Sheng
    ONCOLOGY LETTERS, 2015, 9 (02) : 735 - 738
  • [22] The JAK2 V617F Mutation in Pediatric Myeloproliferative Neoplasms: How and When?
    Langabeer, Stephen E.
    Smith, Owen P.
    McMahon, Corrina
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 31 (02) : 138 - 139
  • [23] JAK2 V617F Mutation Prevalence in Myeloproliferative Neoplasms in Pernambuco, Brazil
    da Silva, Rafael Ramos
    Domingues Hatzlhofer, Betania Lucena
    de Faria Machado, Cintia Gonsalves
    de Melo Lima, Aleide Santos
    de Albuquerque, Dulcineia Martins
    Nunes dos Santos, Magnun Nueldo
    Fertrin, Kleber Yotsumoto
    Costa, Fernando Ferreira
    Araujo, Aderson da Silva
    Cavalcanti Bezerra, Marcos Andre
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (07) : 802 - 805
  • [24] New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
    Zhang, Yongchao
    Zhao, Yue
    Liu, YuSi
    Zhang, Minyu
    Zhang, Jihong
    CANCER, 2024, 130 (24) : 4229 - 4240
  • [25] Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
    Chadi, Soumaya
    Dhaouadi, Tarak
    Sfar, Imen
    Baccouche, Hela
    Nabli, Rym
    Ben Romdhane, Neila
    Ben Abdallah, Taieb
    Gorgi, Yousr
    EUROPEAN JOURNAL OF INFLAMMATION, 2021, 19
  • [26] Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.
    Shide, Kotaro
    Kameda, Takuro
    Markovtsov, Vadim
    Matsunaga, Takuya
    Shimoda, Haruko
    Hidaka, Tomonori
    Katayose, Keiko
    Kubuki, Yoko
    Bhamidipati, Somasekhar
    Park, Gary
    Torneros, Allan
    Duan, Matt
    Hitoshi, Yasumichi
    Shimoda, Kazuya
    BLOOD, 2009, 114 (22) : 1499 - 1499
  • [27] Pitpβ Loss Ameliorates Jak2 V617F-Induced Myeloproliferative Neoplasms (MPN) in Mice
    Vantsev, Nikita
    Zhao, Liang
    Abrams, Charles S.
    Tong, Wei
    BLOOD, 2024, 144 : 1753 - 1754
  • [28] The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm
    Sangkhae, Veena
    Etheridge, S. Leah
    Kaushansky, Kenneth
    Hitchcock, Ian S.
    BLOOD, 2014, 124 (26) : 3956 - 3963
  • [29] JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment
    Pacilli, Annalisa
    Guglielmelli, Paola
    Fanelli, Tiziana
    Pancrazzi, Alessandro
    Pieri, Lisa
    Fjerza, Rajmonda
    Vannucchi, Alessandro M.
    BLOOD, 2015, 126 (23)
  • [30] JAK2V617F CLONAL ARCHITECTURE IN MPNs DURING JAK2 INHIBITOR TREATMENT
    Pacilli, A.
    Rabuzzi, C.
    Guglielmelli, P.
    Fanelli, T.
    Pancrazzi, A.
    Pieri, L.
    Fierza, R.
    Bosi, A.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 107 - 108
12345